Evidence map›Paper›PMID 25424584›Full record

ArticleScientific reports2014

Integrating computational modeling and functional assays to decipher the structure-function relationship of influenza virus PB1 protein.

Chunfeng Li, Aiping Wu, Yousong Peng, Jingfeng Wang, Yang Guo, Zhigao Chen, Hong Zhang, Yongqiang Wang, Jiuhong Dong, Lulan Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Chunfeng Li1] Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing. 100005, China [2] Suzhou Institute of Systems Medicine, Suzhou. 215123, China.
Aiping Wu1] Suzhou Institute of Systems Medicine, Suzhou. 215123, China [2] Key Laboratory of Protein &Peptide Pharmaceuticals, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing. 100101, China.
Yousong PengCollege of Computer Science and Electronic Engineering, Hunan University, Changsha. 410082, China.
Jingfeng WangSuzhou Institute of Systems Medicine, Suzhou. 215123, China.
Yang GuoMOH Key Laboratory of Systems Biology of Pahogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, 100730, China.
Zhigao ChenCenter of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing. 100005, China.
Hong ZhangKey Laboratory of Protein &Peptide Pharmaceuticals, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing. 100101, China.
Yongqiang WangKey Laboratory of Protein &Peptide Pharmaceuticals, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing. 100101, China.
Jiuhong DongKey Laboratory of Protein &Peptide Pharmaceuticals, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing. 100101, China.
Lulan WangCenter of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing. 100005, China.
F Xiao-Feng Qin1] Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing. 100005, China [2] Suzhou Institute of Systems Medicine, Suzhou. 215123, China.
Genhong Cheng1] Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing. 100005, China [2] Suzhou Institute of Systems Medicine, Suzhou. 215123, China [3] Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Tao DengMOH Key Laboratory of Systems Biology of Pahogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, 100730, China.
Taijiao Jiang1] Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing. 100005, China [2] Suzhou Institute of Systems Medicine, Suzhou. 215123, China [3] Key Laboratory of Protein &Peptide Pharmaceuticals, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing. 100101, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNSuzhou Institute of Systems Medicine · CNChinese Academy of Sciences · CNHunan University · CNInstitute of Biophysics · CN

Funding

Viral Mediated Type I Interferon InductionR01AI069120 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2006 to 2021
$6.0M
Role of IRF3 and RXRa Crosstalk in Host Response to Viral InfectionsR01AI078389 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2009 to 2013
$1.8M
NIAID NIH HHS AI069120NIAID NIH HHS R01 AI069120NIAID NIH HHS R01 AI078389
6 · The paper itself

Abstract

The influenza virus PB1 protein is the core subunit of the heterotrimeric polymerase complex (PA, PB1 and PB2) in which PB1 is responsible for catalyzing RNA polymerization and binding to the viral RNA promoter. Among the three subunits, PB1 is the least known subunit so far in terms of its structural information. In this work, by integrating template-based structural modeling approach with all known sequence and functional information about the PB1 protein, we constructed a modeled structure of PB1. Based on this model, we performed mutagenesis analysis for the key residues that constitute the RNA template binding and catalytic (TBC) channel in an RNP reconstitution system. The results correlated well with the model and further identified new residues of PB1 that are critical for RNA synthesis. Moreover, we derived 5 peptides from the sequence of PB1 that form the TBC channel and 4 of them can inhibit the viral RNA polymerase activity. Interestingly, we found that one of them named PB1(491-515) can inhibit influenza virus replication by disrupting viral RNA promoter binding activity of polymerase. Therefore, this study has not only deepened our understanding of structure-function relationship of PB1, but also promoted the development of novel therapeutics against influenza virus.

Indexed as

Models, ChemicalAmino Acid SequenceComputer SimulationEnzyme ActivationEnzyme StabilityModels, MolecularMolecular Sequence DataPromoter Regions, GeneticProtein BindingProtein ConformationProtein Structure, TertiaryRNA, ViralSequence Analysis, ProteinStructure-Activity RelationshipSystems IntegrationViral Proteinsinfluenza virus polymerase basic protein 1RNA, ViralViral Proteins

Identifiers

PMID25424584
PMCPMC4244630
OpenAlexW2087519702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.